潜能恒信：10月23日召开董事会会议

Group 1 - The core point of the article is that Qianeng Hengxin (SZ 300191) held its ninth meeting of the sixth board of directors on October 23, 2025, to review the proposal for amending the company's articles of association [1] - For the year 2024, the revenue composition of Qianeng Hengxin is as follows: oil and gas extraction accounts for 97.03%, petroleum exploration technical services account for 2.1%, and leasing accounts for 0.87% [1] - As of the time of reporting, Qianeng Hengxin has a market capitalization of 6.8 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangdong Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]